Neuren Pharmaceuticals Ltd (NEU) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Neuren Pharmaceuticals Ltd stock A$14.02, price A$20.97, that is 33.1% below the price, quality 60 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
Neuren Pharmaceuticals Ltd
NEU · AUExpensive (fair value 33% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.
How to read this chart
60‑month range A$1.63 – A$24.93 · fair‑value band A$9.82 – A$18.24 · the A$20.97 price screens above the A$14.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.
Every Wednesday you see whether Neuren Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
Show moreShow less
It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.
In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Stock analysis
Neuren Pharmaceuticals Ltd (NEU) currently trades at A$20.97, while our model-based Fair Value estimate is A$14.02, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$17.14 per share, and 0 of the 23 models we run sit above the A$20.97 price.
Bear case: the Economic Profit group reads lowest at A$1.51, and 23 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: A$9.82 (bear) to A$18.24 (bull), the price of A$20.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neuren Pharmaceuticals Ltd reported revenue of A$64.6M in FY2025 versus A$3.2M in FY2021, a compound +112.0%/yr. Reported net income was A$30.4M in FY2025.
Key figures
Market cap A$2.7B (≈ $1.8B) Small · P/E ratio 139.8 · P/S ratio 38.4 · EPS (TTM) A$0.15 · Dividend yield 0.7% · Net margin 29.1% · Return on equity 6.2% · Return on assets (EBIT) 17.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 87% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −33%, NEU screens richer than that median.
Fair Value models
All 23 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Compare Neuren Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Valuation of the Australia market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $920.69 | $1,275.02 | +38% | vs NEU |
| Vertex Pharmaceuticals Incorporated VRTX | $515.02 | $566.52 | +10% | vs NEU |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,490,500 | +10% | vs NEU |
| argenx SE ARGX | $925.70 | $908.40 | −2% | vs NEU |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs NEU |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs NEU |
| Moderna, Inc MRNA | $195.00 | $119.97 | −38% | vs NEU |
| Revolution Medicines, Inc RVMD | $161.20 | $83.14 | −48% | vs NEU |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs NEU |
| Royalty Pharma plc RPRX | $68.45 | $19.01 | −72% | vs NEU |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Neuren Pharmaceuticals Ltd (NEU) overvalued or undervalued?
What is the fair value of NEU?
What is the quality score of NEU?
What is the price target for Neuren Pharmaceuticals Ltd (NEU)?
What is the Neuren Pharmaceuticals Ltd stock forecast for 2026?
What is the revenue of Neuren Pharmaceuticals Ltd (NEU)?
Does Neuren Pharmaceuticals Ltd pay a dividend?
How much is the dividend of Neuren Pharmaceuticals Ltd (NEU) and when is the ex-dividend date?
What growth is priced into Neuren Pharmaceuticals Ltd (NEU)?
What discount rate (WACC) does the fair value of NEU use?
What is a reverse DCF?
How much growth has Neuren Pharmaceuticals Ltd (NEU) delivered so far?
How fast is the sector of Neuren Pharmaceuticals Ltd (NEU) growing?
What is the free cash flow yield of Neuren Pharmaceuticals Ltd (NEU)?
What is the intrinsic value of Neuren Pharmaceuticals Ltd (NEU)?
Is Neuren Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of NEU?
How much is Neuren Pharmaceuticals Ltd worth?
What do the bullish and bearish scenarios say about NEU?
What is the P/E ratio of NEU?
How solid is the balance sheet of Neuren Pharmaceuticals Ltd (NEU)?
How far is NEU from its 52-week high?
Which stocks are comparable to Neuren Pharmaceuticals Ltd?
Is Neuren Pharmaceuticals Ltd stock attractive at the current price?
How is the fair value of NEU calculated?
Is it still worth investing in stocks now?
What is the share price of Neuren Pharmaceuticals Ltd (NEU)?
What should I pay attention to with Neuren Pharmaceuticals Ltd right now?
Key figures of Neuren Pharmaceuticals Ltd
How large is the market capitalisation of Neuren Pharmaceuticals Ltd (NEU)?
What is the P/S ratio of Neuren Pharmaceuticals Ltd (NEU)?
What are the earnings per share of Neuren Pharmaceuticals Ltd (NEU)?
What is the dividend yield of Neuren Pharmaceuticals Ltd (NEU)?
What is the net margin of Neuren Pharmaceuticals Ltd (NEU)?
What is the return on equity of Neuren Pharmaceuticals Ltd (NEU)?
What is the EBIT return on assets of Neuren Pharmaceuticals Ltd (NEU)?
What is the operating margin of Neuren Pharmaceuticals Ltd (NEU)?
How fast is revenue growing at Neuren Pharmaceuticals Ltd (NEU)?
How fast are earnings growing at Neuren Pharmaceuticals Ltd (NEU)?
How much net cash does Neuren Pharmaceuticals Ltd (NEU) hold?
Watch Neuren Pharmaceuticals Ltd in the live analysis
One click puts Neuren Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.